Biosynex SA (EPA:ALBIO)

Market Cap	17.32M +38.1%
Revenue (ttm)	97.95M -5.9%
Net Income	-70.99M
EPS	-4.82
Shares Out	18.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,396
Average Volume	89,457
Open	0.9220
Previous Close	0.9240
Day's Range	0.9220 - 0.9860
52-Week Range	0.4550 - 1.9800
Beta	0.83
RSI	53.93
Earnings Date	Apr 30, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products. The company was founded in 1993 and is based in Illkirch-Graf...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1993
• Employees: 454
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALBIO

Financial Performance

In 2024, Biosynex's revenue was 101.17 million, an increase of 8.81% compared to the previous year's 92.98 million. Losses were -43.33 million, 17.3% more than in 2023.